ARCT
Price
$17.01
Change
-$0.29 (-1.68%)
Updated
Aug 29 closing price
Capitalization
461.9M
64 days until earnings call
DMAC
Price
$5.71
Change
-$0.16 (-2.73%)
Updated
Aug 29 closing price
Capitalization
295.14M
64 days until earnings call
Interact to see
Advertisement

ARCT vs DMAC

Header iconARCT vs DMAC Comparison
Open Charts ARCT vs DMACBanner chart's image
Arcturus Therapeutics Holdings
Price$17.01
Change-$0.29 (-1.68%)
Volume$523.4K
Capitalization461.9M
DiaMedica Therapeutics
Price$5.71
Change-$0.16 (-2.73%)
Volume$118.77K
Capitalization295.14M
ARCT vs DMAC Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. DMAC commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and DMAC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (ARCT: $17.01 vs. DMAC: $5.71)
Brand notoriety: ARCT and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 91% vs. DMAC: 30%
Market capitalization -- ARCT: $461.9M vs. DMAC: $295.14M
ARCT [@Biotechnology] is valued at $461.9M. DMAC’s [@Biotechnology] market capitalization is $295.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while DMAC’s TA Score has 2 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • DMAC’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than DMAC.

Price Growth

ARCT (@Biotechnology) experienced а -8.10% price change this week, while DMAC (@Biotechnology) price change was -6.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.59%, and the average quarterly price growth was +30.71%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($462M) has a higher market cap than DMAC($295M). DMAC YTD gains are higher at: 5.157 vs. ARCT (0.236). DMAC has higher annual earnings (EBITDA): -31.42M vs. ARCT (-54.54M). ARCT has more cash in the bank: 196M vs. DMAC (30M). DMAC has less debt than ARCT: DMAC (292K) vs ARCT (27M). ARCT has higher revenues than DMAC: ARCT (110M) vs DMAC (0).
ARCTDMACARCT / DMAC
Capitalization462M295M157%
EBITDA-54.54M-31.42M174%
Gain YTD0.2365.1575%
P/E RatioN/AN/A-
Revenue110M0-
Total Cash196M30M653%
Total Debt27M292K9,247%
FUNDAMENTALS RATINGS
ARCT vs DMAC: Fundamental Ratings
ARCT
DMAC
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4240
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (44) in the Pharmaceuticals Major industry is in the same range as DMAC (67) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as DMAC (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as DMAC (98) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Price Growth Rating (40) in the Biotechnology industry is in the same range as ARCT (42) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to ARCT’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTDMAC
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
81%
Momentum
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 5 days ago
83%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
85%
Aroon
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PETZX14.870.06
+0.41%
Gabelli Pet Parents'™
THOFX46.020.11
+0.24%
Thornburg Global Opportunities R5
FRINX12.21N/A
N/A
Fidelity Advisor Real Estate Income A
MNBWX20.66-0.06
-0.29%
Manning & Napier Pro-Blend Extnd Term W
DHIIX20.14-0.08
-0.40%
Diamond Hill International I

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RGNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-1.68%
RGNX - ARCT
51%
Loosely correlated
-0.89%
CLDX - ARCT
49%
Loosely correlated
-1.34%
RXRX - ARCT
46%
Loosely correlated
-3.39%
MRNA - ARCT
46%
Loosely correlated
-1.55%
MGNX - ARCT
46%
Loosely correlated
+4.12%
More

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
-2.73%
WHWK - DMAC
47%
Loosely correlated
+1.98%
ARCT - DMAC
38%
Loosely correlated
-1.68%
HUMA - DMAC
36%
Loosely correlated
-1.90%
VICP - DMAC
33%
Poorly correlated
N/A
LQDA - DMAC
33%
Poorly correlated
+0.80%
More